JNJ Gene Therapy Push Tackles Rare Disease Gap
Johnson & Johnson (JNJ) is pushing forward in gene therapy and AI repurposing, advancing its candidate Botaretigene sparoparvovec for X-linked retinitis pigmentosa. This move fits into the company's broader strategy of developing specialized treatments for rare diseases.
The pharmaceutical giant is expanding its work on drug repurposing programs that use AI tools to reanalyze existing compounds for oncology and rare diseases. Management has taken a leading role in global collaborations focused on AI-driven compound repurposing, adding to the company's research footprint in this area.
Johnson & Johnson's push into gene therapy and AI-led drug repurposing may indicate a shift towards durable specialty therapies, which could support its narrative of accelerated growth. However, some risks remain, including tariffs, litigation, and competition from STELARA.